CLOs on the Move

Intellikine

www.intellikine.com

 
Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.intellikine.com
  • 10931 N Torrey Pines Rd Ste 103
    La Jolla, CA USA 92037
  • Phone: 858.768.6500

Executives

Name Title Contact Details

Similar Companies

LA Habilitation House

LA Habilitation House is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eccrine Systems

Eccrine Systems, Inc., is focused on the development of non-invasive disposable electronic patches that accurately measure and transmit real-time data about human sweat. Applications for our technology and IP span market opportunities within medicine, industry, and sports. We seek to establish exclusive collaborations with downstream partners who understand the opportunity for embedding and deploying our technology in their market-specific applications. Our role in these collaborations is the modular development and prototyping of desired sweat sensor features and capabilities. Our partners embed our technology in their commercial applications and translate data about sweat and other biometrics into high value products for their customers.

Nanogen, Inc.

Nanogen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Better Therapeutics

Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.